Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Share-based Compensation (2020 - 2022)

Historic Share-based Compensation for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q4 2022 value amounting to $11.6 million.

  • Atea Pharmaceuticals' Share-based Compensation rose 259.01% to $11.6 million in Q4 2022 from the same period last year, while for Dec 2022 it was $46.7 million, marking a year-over-year increase of 1791.22%. This contributed to the annual value of $51.8 million for FY2024, which is 473.21% up from last year.
  • Per Atea Pharmaceuticals' latest filing, its Share-based Compensation stood at $11.6 million for Q4 2022, which was up 259.01% from $11.5 million recorded in Q3 2022.
  • Over the past 5 years, Atea Pharmaceuticals' Share-based Compensation peaked at $11.9 million during Q2 2022, and registered a low of $189000.0 during Q1 2020.
  • Its 3-year average for Share-based Compensation is $7.8 million, with a median of $10.5 million in 2021.
  • Its Share-based Compensation has fluctuated over the past 5 years, first soared by 468803.83% in 2021, then skyrocketed by 259.01% in 2022.
  • Over the past 3 years, Atea Pharmaceuticals' Share-based Compensation (Quarter) stood at $2.8 million in 2020, then skyrocketed by 302.38% to $11.4 million in 2021, then grew by 2.59% to $11.6 million in 2022.
  • Its Share-based Compensation stands at $11.6 million for Q4 2022, versus $11.5 million for Q3 2022 and $11.9 million for Q2 2022.